Clinical Trial Update: TMC435350-TiDP16-C106: A Phase I Trial to Compare the Bioavailability and Plasma Pharmacokinetics After a Single Oral Dose of TMC435350 of 2 Different Solid Formulations Relative to a Powder Blend Capsule [Phase 1]

View source ↗

Summary

A Phase I study comparing the bioavailability and pharmacokinetics of two solid formulations of TMC435350 versus a powder blend capsule in Hepatitis C patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435350

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C, HCV | Phase 1 | Status: COMPLETED